Guardant Health Lands $100,000,000 Series D Funding Round

  • Feed Type
  • Date
  • Company Name
    Guardant Health
  • Mailing Address
    505 Penobscot Dr. Redwood City, CA 94063 USA
  • Company Description
    Guardant360 is the only biopsy-free tumor sequencing test that tracks tumor genomics in real-time and identifies associated treatment options.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series D
  • Proceeds Purposes
    The funding will help Guardant Health build on its leading technological and commercial positions to further expand the adoption of Guardant360, the world’s first comprehensive, non-invasive genomic sequencing test for cancer. The investment will go toward Guardant Health’s Digital Sequencing platform to power additional breakthrough products geared toward addressing the full spectrum of the cancer-care continuum.
  • M&A Terms
  • Venture Investor
  • Venture Investor
    Khosla Ventures
  • Venture Investor
    Sequoia Capital
  • Venture Investor
    Lightspeed Venture Partners
  • Venture Investor
    Pejman Mar Ventures
  • Venture Investor
    Formation 8
  • Venture Investor
    Heritage Group
  • Venture Investor
    Felicis Ventures

Trending on Xconomy